DE3868438D1 - Cyclosporin enthaltende pharmazeutische zubereitung. - Google Patents

Cyclosporin enthaltende pharmazeutische zubereitung.

Info

Publication number
DE3868438D1
DE3868438D1 DE8888305138T DE3868438T DE3868438D1 DE 3868438 D1 DE3868438 D1 DE 3868438D1 DE 8888305138 T DE8888305138 T DE 8888305138T DE 3868438 T DE3868438 T DE 3868438T DE 3868438 D1 DE3868438 D1 DE 3868438D1
Authority
DE
Germany
Prior art keywords
pharmaceutical preparation
preparation containing
containing cyclosporine
cyclosporine
cyclosporins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8888305138T
Other languages
German (de)
English (en)
Inventor
Kozo Kurihara
Masaru Murano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co Ltd filed Critical Sankyo Co Ltd
Application granted granted Critical
Publication of DE3868438D1 publication Critical patent/DE3868438D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DE8888305138T 1987-06-04 1988-06-06 Cyclosporin enthaltende pharmazeutische zubereitung. Expired - Lifetime DE3868438D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP14070387 1987-06-04

Publications (1)

Publication Number Publication Date
DE3868438D1 true DE3868438D1 (de) 1992-03-26

Family

ID=15274767

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8888305138T Expired - Lifetime DE3868438D1 (de) 1987-06-04 1988-06-06 Cyclosporin enthaltende pharmazeutische zubereitung.

Country Status (10)

Country Link
US (1) US5051402A (enExample)
EP (1) EP0294239B1 (enExample)
JP (1) JP2577049B2 (enExample)
AT (1) ATE72629T1 (enExample)
AU (1) AU607506B2 (enExample)
CA (1) CA1325973C (enExample)
DE (1) DE3868438D1 (enExample)
ES (1) ES2033429T3 (enExample)
GR (1) GR3004199T3 (enExample)
HK (1) HK28097A (enExample)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
JPH07111785B2 (ja) 1990-01-19 1995-11-29 富士通株式会社 光ディスク
US5227372A (en) * 1990-03-07 1993-07-13 Children's Medical Center Corporation Method for retaining ophthalmological agents in ocular tissues
HU208491B (en) * 1990-11-27 1993-11-29 Gyogyszerkutato Intezet Process for producing oral pharmaceutical composition containing cyclosporin
FR2670629B1 (fr) * 1990-12-17 1995-03-10 Moving Magnet Tech Actionneur electromagnetique monophase rotatif.
DE69222150T2 (de) * 1991-01-25 1998-01-15 Fujisawa Pharmaceutical Co Prozess zur produktion von cyclosporin-a und/oder c
SG45449A1 (en) * 1992-05-13 1998-01-16 Sandoz Ltd Ophthalmic compositions
US5494901A (en) * 1993-01-05 1996-02-27 Javitt; Jonathan C. Topical compositions for the eye comprising a β-cyclodextrin derivative and a therapeutic agent
NZ247516A (en) * 1993-04-28 1995-02-24 Bernard Charles Sherman Water dispersible pharmaceutical compositions comprising drug dissolved in solvent system comprising at least one alcohol and at least one surfactant
US5474979A (en) * 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
WO1995032726A1 (en) * 1994-06-01 1995-12-07 Yuhan Corporation Cyclosporin containing composition and process for the preparation thereof
KR0167613B1 (ko) * 1994-12-28 1999-01-15 한스 루돌프 하우스, 니콜 케르커 사이클로스포린-함유 연질캅셀제 조성물
JP2007056045A (ja) * 1995-05-26 2007-03-08 Nobaruteisu Fuaama Kk サイクロデキストリン組成物
JP3934705B2 (ja) * 1995-05-26 2007-06-20 ノバルティス ファーマ株式会社 サイクロデキストリン組成物
US5827822A (en) * 1996-03-25 1998-10-27 Sangstat Medical Corporation Cyclosporin a formulations as nanoparticles
US5962019A (en) * 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
US5834017A (en) * 1995-08-25 1998-11-10 Sangstat Medical Corporation Oral cyclopsporin formulations
US5766629A (en) * 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US20070185032A1 (en) * 1996-12-11 2007-08-09 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
PT988046E (pt) * 1997-01-30 2004-12-31 Novartis Ag Composicoes farmaceuticas sem oleo contendo ciclosporina a
NZ328751A (en) 1997-09-16 1999-01-28 Bernard Charles Sherman Solid medicament containing an anionic surfactant and cyclosporin
DE69832984T2 (de) 1997-10-08 2006-09-21 Isotechnika, Inc., Edmonton DEUTERIERtE und undeuterierte CYCLOSPORIN-ANALOGA UND IHRE VERWENDUNG ALS IMMUNMODULIERENDE AGENtIEN
US20030220234A1 (en) * 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
TW581681B (en) * 1998-02-20 2004-04-01 Nektar Therapeutics Liquid crystal forms of cyclosporin
US20040152664A1 (en) * 1998-09-02 2004-08-05 Allergan, Inc. Prednisolone compositions
WO2000012137A1 (en) * 1998-09-02 2000-03-09 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
EP1435910B9 (en) * 2001-10-19 2010-02-03 Isotechnika Inc. Novel cyclosporin analog microemulsion preconcentrates
HRP20070058B1 (hr) 2001-10-19 2014-05-23 Isotechnika Inc. Sinteza ciklosporinskih analoga
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
US20050112087A1 (en) * 2003-04-29 2005-05-26 Musso Gary F. Pharmaceutical formulations for sustained drug delivery
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
JP2007512337A (ja) 2003-11-21 2007-05-17 コンビナトアールエックス インコーポレーティッド 炎症性障害の治療のための方法および試薬
US7691812B2 (en) * 2004-11-04 2010-04-06 Trustees Of The University Of Pennsylvania Methods for inhibiting growth of prolactin-responsive cancer cells with cyclosporine A or other cyclophilin inhibitors
US7288520B2 (en) * 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
US7297679B2 (en) * 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
US20070015691A1 (en) * 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US7202209B2 (en) 2005-07-13 2007-04-10 Allergan, Inc. Cyclosporin compositions
US7276476B2 (en) * 2005-07-13 2007-10-02 Allergan, Inc. Cyclosporin compositions
US20070015693A1 (en) * 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
WO2007011880A2 (en) 2005-07-18 2007-01-25 Minu, L.L.C. Enhanced ocular neuroprotection/neurostimulation
US7501393B2 (en) 2005-07-27 2009-03-10 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US7745400B2 (en) * 2005-10-14 2010-06-29 Gregg Feinerman Prevention and treatment of ocular side effects with a cyclosporin
US8067433B2 (en) 2005-11-09 2011-11-29 Zalicus Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
DE102006051512A1 (de) 2005-12-06 2007-06-14 Pari GmbH Spezialisten für effektive Inhalation Pharmazeutische Medikamentenzusammensetzungen mit Cyclosporin
FI118537B (fi) * 2006-03-08 2007-12-14 Kuopion Yliopisto Menetelmä syklodekstriinin kompleksoitumisen lisäämiseksi
US9561178B2 (en) * 2006-07-25 2017-02-07 Allergan, Inc. Cyclosporin compositions
US20080146497A1 (en) * 2006-07-25 2008-06-19 Graham Richard S Cyclosporin Compositions
AU2016203191B2 (en) * 2006-07-25 2018-03-01 Allergan, Inc. Cyclosporin compositions
CN101896160A (zh) * 2006-10-17 2010-11-24 阿勒根公司 环胞菌素组合物
JP5668476B2 (ja) 2007-10-08 2015-02-12 オーリニア・ファーマシューティカルズ・インコーポレイテッドAurinia Pharmaceuticals Inc. カルシニューリン阻害剤またはmTOR阻害剤を含む眼科用組成物
US20100016219A1 (en) * 2008-07-19 2010-01-21 Jerry Zhang Ophthalmic compositions containing solubilized cyclosporin
EP2440185B1 (en) 2009-06-09 2015-04-08 Aurinia Pharmaceuticals Inc. Topical drug delivery systems for ophthalmic use
KR20140054005A (ko) * 2011-06-29 2014-05-08 알러간, 인코포레이티드 마크로골 15 하이드록시스테아레이트 제형
AU2016272700A1 (en) * 2015-05-29 2017-12-14 Oculis ehf. Formation of cyclosporin A/cyclodextrin nanoparticles
CN105997863B (zh) * 2016-07-21 2018-09-04 河南省眼科研究所 环孢素a滴眼液及其制备方法
PT3548091T (pt) 2016-11-29 2022-01-21 Oculis SA Preparação de complexos sólidos de ciclodextrina para administração oftálmica de ingrediente farmacêutico ativo
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
WO2021001366A1 (en) 2019-07-01 2021-01-07 Oculis SA Method for stabilizing the ph of an aqueous composition comprising a drug
CN112724200B (zh) * 2019-10-28 2022-09-27 上海云泽生物科技有限公司 一种稳定环孢霉素a的稀释液及其应用
CN116390762B (zh) 2020-11-09 2026-05-08 思凯制药有限公司 固体环孢菌素a和包含其的分散组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4117118A (en) * 1976-04-09 1978-09-26 Sandoz Ltd. Organic compounds
FI65914C (fi) * 1978-03-07 1984-08-10 Sandoz Ag Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a
AU558155B2 (en) * 1982-02-01 1987-01-22 Sandoz Ltd. Treating multiple sclerosis with dihydro-cyclosporin d
EP0094157B1 (en) * 1982-04-30 1987-07-29 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its use
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
DE3580717D1 (de) * 1984-08-02 1991-01-10 Sandoz Ag Pharmazeutische anwendung von (nva)2-cyclosporine.

Also Published As

Publication number Publication date
JPS6485921A (en) 1989-03-30
CA1325973C (en) 1994-01-11
ES2033429T3 (es) 1993-03-16
JP2577049B2 (ja) 1997-01-29
EP0294239B1 (en) 1992-02-19
EP0294239A1 (en) 1988-12-07
HK28097A (en) 1997-03-06
US5051402A (en) 1991-09-24
AU607506B2 (en) 1991-03-07
AU1738688A (en) 1988-12-22
GR3004199T3 (enExample) 1993-03-31
ATE72629T1 (de) 1992-03-15

Similar Documents

Publication Publication Date Title
ATE72629T1 (de) Cyclosporin enthaltende pharmazeutische zubereitung.
ES2020738A6 (es) Composiciones farmaceuticas comprendiendo ciclosporinas.
NO883926D0 (no) Fremgangsmaate for fremstilling av stabilisert humanproteinpreparat.
ES2033086T3 (es) Un procedimiento para la preparacion de una composicion farmaceutica.
ATE203411T1 (de) Lagerstabile wässrige pharmazeutische zubereitungen von g-csf
DE69829175D1 (de) Cyclosporinderivate, deren herstellung und pharmazeutische zubereitungen
SE9503143D0 (sv) New preparation
MY101593A (en) Sustained release preparation.
ATE109145T1 (de) Heterozyklische acylaminothiazolderivate, ihre herstellung und diese enthaltende pharmazeutische zubereitungen.
SE8504945D0 (sv) Pharmaceutical compositions containing anthracycline glycosides
DE3875108D1 (de) Physiologisch aktives polypeptid und pharmazeutische komposition.
WO1991015512A3 (en) Hiv envelope polypeptides
DK1027053T3 (da) Fremgangsmåde til forebyggelse af nefrotoksicitet forårsaget af cyclosporiner eller tacrolimuser
PT88539A (pt) Stabilisierung von therapeutisch wirksamen proteinen in pharmazeutischen zubereitungen
ATE70445T1 (de) Pharmazeutische praeparate.
RU96114157A (ru) Способ лечения острых отравлений
ATE342734T1 (de) Adenosin a1 antagonisten gegen männliche sterilität
SE8902458L (sv) Laekemedelskomposition
KR900011461A (ko) 트립스타틴을 유효성분으로 하는 치료제
RU96106437A (ru) Способ лечения сухой остаточной полости после перенесенного абсцесса легкого
ES2060057T3 (es) Soluciones acuosas conteniendo proteina.
FR2572932B1 (fr) Medicament insoluble administre localement dans l'oreille
DE59007260D1 (de) Pharmazeutische zubereitung zur rektalen verabreichung.
JPS6461429A (en) Remedy for cancer
DE3865642D1 (de) Pharmazeutische zubereitung zur cholelitholyse.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: NOVARTIS AG, BASEL, CH

8328 Change in the person/name/address of the agent

Free format text: STREHL, SCHUEBEL-HOPF & PARTNER, 80538 MUENCHEN